title: [Treatment of seronegative myasthenia garvis].
abstract: Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction. It is classified into 1) the nicotinic acetylcholine receptor antibodies (80-85%), 2) muscle- specific tyrosine kinase antibodies (5-10%), and 3) the above-mentioned antibody absent, double seronegative MG. In this symposium, I focused the treatment of double seronegative MG.
authors.affiliation: First Department of Internal Medicine, Graduate School of Biomedical Sciences, Nagasaki University.
authors.forename: Masakatsu
authors.initials: M
authors.lastname: Motomura
mesh_terms: D001323:Autoantibodies / Q000097:blood; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D009157:Myasthenia Gravis / Q000276:immunology* / Q000628:therapy*; D013256:Steroids / Q000627:therapeutic use; D013934:Thymectomy
chemical_list: D001323:Autoantibodies; D007166:Immunosuppressive Agents; D013256:Steroids